A detailed history of Federated Hermes, Inc. transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 3,006 shares of ANTX stock, worth $4,028. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,006
Previous 917 227.81%
Holding current value
$4,028
Previous $1,000 200.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.98 - $2.96 $2,047 - $6,183
2,089 Added 227.81%
3,006 $3,000
Q2 2024

Aug 08, 2024

BUY
$1.93 - $3.76 $1,362 - $2,654
706 Added 334.6%
917 $1,000
Q1 2024

May 14, 2024

SELL
$2.78 - $21.53 $130 - $1,011
-47 Reduced 18.22%
211 $0
Q4 2023

Jan 31, 2024

BUY
$13.92 - $21.0 $2,227 - $3,360
160 Added 163.27%
258 $5,000
Q3 2023

Nov 13, 2023

BUY
$7.58 - $16.08 $742 - $1,575
98 New
98 $1,000

Others Institutions Holding ANTX

About AN2 Therapeutics, Inc.


  • Ticker ANTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,402,700
  • Market Cap $26M
  • Description
  • AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...
More about ANTX
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.